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OBJECTIVE: To evaluate the cost consequences of
LMWH compared with unfractionated heparin in the
treatment of unstable angina pectoris in Japan.
METHODS: A cost-consequence analysis was performed
using decision-analytic modeling using evidence from the
FRISC (Fragmin during Instability in Coronary Artery
Disease) study group, Sweden. The decision tree models a
patient presenting with unstable angina pectoris and fac-
ing the alternative treatments of LMWH or heparin as a
basic model. Also, an advanced model was constructed
with treatment options that reflected more realistic prac-
tice patterns in Japan. Cardiologists reviewed the model-
development process to make the model relevant to the
Japanese medical environment. The direct costs were ob-
tained from pilot studies of DRGs in Japanese national
hospitals.
RESULTS: In the basic model, we estimated a slight dif-
ference in expected costs between LMWH and heparin,
favoring LMWH. However, this model was limited in
two main areas: 1) difference in effects between LMHW
and heparin were not statistically significant in the FRISC
study; 2) opportunity costs such as monitoring for hep-
arinization and treatment of bleeding with heparin were
not included. When we incorporated realistic assump-
tions regarding the opportunity costs and Japan’s treat-
ment patterns, we found that the total medical costs for
the LMWH group were much lower than for the heparin
group even if the clinical effects for heparin and LMWH
were set as equal. In this case, the estimated cost in the
LMWH group was about $11,300 per patient and
$19,600 for the heparin group assuming LMWH is prop-
erly used in clinical practice. This result was robust to a
range of sensitivity analyses.
CONCLUSION: The use of LMWH for unstable angina
pectoris in actual clinical practice where heparin monitoring
can be avoided appears to be cost-saving in Japan. Consid-
ering the target population of 700,000 patients in Japan, the
LMWH will have a great economic impact on society.
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OBJECTIVE: To quantify and qualify the antihyperten-
sive pharmaceutical expenditure incurred for the treat-
ment of a population in the real world.
METHODS: An administrative database, collecting in-
formation on all purchased drugs, was used to perform a
retrospective analysis for each health-assisted subject by
the Ravenna Local Health Unit. By crosschecking with
the registry office and hospital database, gender, age and
previous hospitalizations for cardiovascular diseases were
also made available. All new users over 20 years old re-
ceiving a first prescription for diuretic, beta-blocker, cal-
cium-channel-blocker, angiotensin-converting-enzyme in-
hibitor or angiotensin II antagonist between 01/01/1997
and 12/31/1997 were included. According to persistency
of treatment, patients were classified as continuers (dura-
tion of therapy over 273 days with the initial antihyper-
tensive class), switchers (duration of therapy over 273
days with a different class of antihypertensive than origi-
nally prescribed) and discontinuers (duration of therapy
less than 273 days). The follow-up period lasted 365
days.
RESULTS: A total of 16,783 patients were enrolled, in-
cluding 7409 men (44.1%) and 9374 women (55.9%)
with an average age of 56.1  18.3 years. Continuers
and switchers represented 26.9% and 8.2% of enrolled
subjects, respectively. The percentage of treatment inter-
ruptions (64.9%) ranged from 42.0% with angiotensin II
antagonists to 69.8% with diuretics, and 53.8% of the
population interrupted therapy after the first prescrip-
tion. Age, co-morbidities and previous hospitalizations were
higher for continuers and switchers than for discontinu-
ers. The overall expenditure accounted for €1,076,053.55
of which 54.8% was for continuers, 19.8% for switchers
and 25.4% for discontinuers. The percentage of the over-
all cost for discontinuers ranged from 14.8% with angio-
tensin II antagonists to 30.6% with calcium-channel
blockers.
CONCLUSION: The high percentage of discontinuers
translated into an expense incurred improperly. The high
percentage of interruptions after the first prescription
seemed to indicate that medication prescribed at enroll-
ment was not appropriate.
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Patients’ persistence with chronic treatment is a major
component in the effectiveness assessment.
OBJECTIVE: To evaluate whether the initial choice of
antihypertensive agent impacts newly diagnosed hyper-
tensive patients’ persistence with treatment at one year.
METHODS: The comparisons were between patients ini-
tially prescribed irbesartan, angiotensin II receptor antag-
onists (AIIRA) versus other antihypertensive drugs. We
compared the proportion of patients who remained on
the monotherapy initially prescribed, added to their ini-
tial therapy, switched to another therapy, or discontinued
therapy at one year using chi-squared tests. Monotherapy
